Access cutting-edge head and neck squamous cell carcinoma treatment through this clinical trial at a research site in Nashville. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Nashville location
Preparing your pre-screening questions…
Access head and neck squamous cell carcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related head and neck squamous cell carcinoma treatment provided free
Check if you qualify for this head and neck squamous cell carcinoma clinical trial in Nashville, TN
No-Cost Study Care
Local to Nashville
Convenient for TN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr89 panitumumab \[89Zr panitumumab\]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread of disease from where it first started (primary site) to other places in the body (metastasis) in patients with head and neck squamous cell carcinoma. Traditional PET/CT has a low positive predictive value for diagnosing metastatic disease in head and neck cancer. 89Zr panitumumab is an investigational imaging agent that contains radiolabeled anti-EGFR antibody which is overexpressed in head and neck cancer. The main question this study aims to answer is the sensitivity and specificity of 89Zr panitumumab for the detection of indeterminate metastatic lesions in head and neck cancer. Participants will receive 89Zr panitumumab infusion and undergo 89Zr panitumumab PET/CT 1 to 5 days after infusion. Participants will otherwise receive standard of care evaluation and treatment for their indeterminate lesions. Researchers will compare the 89Zr panitumumab to standard of care imaging modalities (magnetic resonance imaging (MRI), CT, and/or PET/CT).
Sponsor: Eben Rosenthal
Yes, this clinical trial (NCT05747625) has an active research site in Nashville, TN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for head and neck squamous cell carcinoma treatment options in Nashville, TN, this clinical trial (NCT05747625) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Nashville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced head and neck squamous cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all head and neck squamous cell carcinoma clinical trials near you to find additional studies recruiting in your area.
See all alzheimers disease clinical trials recruiting in Nashville — not just this study.
Browse Alzheimers Disease Trials in Nashville →